This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bijsterveld, N. R. Articles by Peters, R. J. G. Search for Related Content PubMed PubMed Citation Articles by Bijsterveld, N. R. Articles by Peters, R. J. G.

The impact on coagulation of an intravenous loading dose in addition to a subcutaneousregimen of low-molecular-weight heparinin the initial treatment of acute coronary syndromes

Nick R. Bijsterveld, MD^*,*, Arno H. Moons, MD^*, Joost C. M. Meijers, PhD, Marcel Levi, MD, Harry R. Büller, MD and Ron J. G. Peters, MD^*

^* Departments of Cardiology, Amsterdam, The Netherlands
Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

View larger version (15K): [in a new window]   Figure 1 Anti-factor Xa (anti-Xa) levels during the first 24 h of treatment with subcutaneous (SQ) alone (solid circles) or intravenous +SQ (open squares) enoxaparin. Data are presented as the mean value ± SEM. Dotted lines represent the lower and upper therapeutic range (0.5 and 1.0 U/ml, respectively). Significant differences (p < 0.05) using the t test between the two groups are marked with an asterisk.

View larger version (14K): [in a new window]   Figure 2 Thrombin generation time (TGT) during the first 24 h of treatment with subcutaneous (SQ) alone (solid circles) or intravenous +SQ (open squares) enoxaparin. Data are presented as the mean value ± SEM. Significant differences (p < 0.05) using the t test between the two groups are marked with an asterisk.

View larger version (12K): [in a new window]   Figure 3 Levels of prothrombin fragments 1 + 2 (F1+2) during the first 24 h of treatment with subcutaneous (SQ) alone (solid circles) or intravenous +SQ (open squares) enoxaparin. Data are presented as the mean value ± SEM. Significant differences (p < 0.05) using the t test between the two groups are marked with an asterisk.

View larger version (14K): [in a new window]   Figure 4 Activity of tissue factor pathway inhibitor (TFPI) during the first 24 h of treatment with subcutaneous (SQ) alone (solid circles) or intravenous +SQ (open squares) enoxaparin. Data are presented as the mean value ± SEM. Significant differences (p < 0.05) using the t test between the two groups are marked with an asterisk.